GSK leads global forum to address respiratory health challenges

Dr. Gur Levy, respiratory medical expert at GSK said, “We have been pioneering efforts for decades to develop new therapeutic alternatives that set the standard for next-generation treatments and redefine the future of respiratory medicines for hundreds of millions of people with respiratory diseases.”

Through collaboration with leading specialist physicians and experts globally, GSK has developed a world-class programme aimed at achieving excellence in clinical practices and optimising outcomes for patients with respiratory conditions.

Experts participating in discussion at this annual RespiVerse Meeting. Photo: GSK

“We research and develop a portfolio of vaccines, targeted biological products, and inhaled medicines at the forefront of the respiratory sector. By leveraging the latest scientific and technological advances, we aim to address the underlying dysfunction of these diseases and prevent their progression, ultimately improving outcomes for people with asthma, COPD, and RSV,” added Levy.

This year’s RespiVerse meeting featured prominent international speakers and participants from Southeast Asia, Latin America, Central America, and beyond. The programme integrated science, technology, and talent to identify key clinical challenges in the respiratory field, enhancing the knowledge and practices of pulmonologists across Southeast Asia, the Middle East, Africa, and Latin America.

Dr. Gur Levy, Respiratory Medical Expert at GSK. Photo: GSK

The expert panel focused on four respiratory pathologies: moderate asthma, severe asthma, chronic obstructive pulmonary disease (COPD), and respiratory syncytial virus (RSV).

Dr. Arnas Berzanskis, vice president and regional medical affairs head – vaccines at GSK said, “At GSK, we are dedicated to advancing innovative solutions to protect vulnerable populations, particularly older adults and those with underlying medical conditions such as asthma, COPD, diabetes, and heart disease, from RSV and other acute respiratory infections. By prioritising prevention, we aim to ease the burden on healthcare systems and promote healthier communities worldwide, particularly as the global population ages.”

Dr. Arnas Berzanskis, VP & Regional Medical Affairs Head – Vaccines at GSK. Photo: GSK

The event included a special media session featuring renowned experts such as Dr. Le Khac Bao, deputy head of Lung Disease Department, Gia Dinh People's Hospital in Vietnam; Dr. Fariz Nurwidya, chairman and associate professor in Pulmonology and Respiratory Medicine at Universitas Indonesia and pulmonologist at Persahabatan and Bunda General Hospitals in Jakarta; and Dr. Pailin Ratanawatkul, assistant professor in Pulmonary and Critical Care Medicine and associate director of the Center of Excellence at Srinagarind Hospital, Khon Kaen University in Thailand. They explored the causes and consequences of respiratory diseases and discussed ongoing challenges.

Dr. Le Khac Bao, deputy head of Lung Disease Department, Gia Dinh People's Hospital. Photo: GSK

COPD treatment is of utmost importance Professor Paul Jones, emeritus professor of Respiratory Medicine at St George’s University of London, shared his perspectives with VIR’s Bich Thuy on chronic obstructive pulmonary disease (COPD) and a new breakthrough solution to help reduce the burden on patients and the healthcare sector in Vietnam.

GSK: from treatment to prevention for healthy ageing Dr. Pham Thi My Lien, president of GSK Vietnam, spoke with VIR’s Bich Thuy about the importance of adult vaccinations, one of the most effective interventions contributing to improved quality of life, reducing the burden on healthcare, the economy, and society.

First international summit on shingles prevention held in Vietnam GSK organized a series of international scientific summits for healthcare professionals in emerging markets in three countries in October and November, including Colombia, Dubai (UAE) in October, and Vietnam in collaboration with Vietnam Medical Association in November.